TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maximum concentration (Cmax) of huJCAR014 cells in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline on the Brief Pain Inventory (BPI) 24-Hour Average Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 or Higher Cy/GVAX-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Thrombolysis in Cerebral Infarction (TICI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Capillary glucose levels changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: A1c measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in QMG score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal Ulcer Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forgotten Joint Score-12 (FJS-12)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient's Joint Perception questionnaire (PJP)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evidence of rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Hemoglobin Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Group differences between Requip and placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS change from baseline
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in Error in Forward Reaching Symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of laboratory confirmed cases of severe rotavirus gastroenteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of serious adverse events (SAEs), including intussusception
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Adverse Events (AEs) > or = to grade 2
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of incisional hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of missing items in questionnaires
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants With Clinically Relevant Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Number of baseline antral follicle count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Duration for corneal surface re-epithelization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival rate after bystander resuscitation
Endpoint domain: Mortality/survival
Primary endpoint: Rate of disease flares/complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of mature follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: rec FSH dose used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in gene expression in prostate tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of first postoperative analgesia requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nausea Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Emesis Severity
Endpoint domain: Adverse events/effects
Primary endpoint: TNF-alpha Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum effect on Drug Liking VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: SUV at atherosclerotic plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time-to-assessment (TTA) for time-critical conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients seen within a clinically appropriate timeframe
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in maternal cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in maternal heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in maternal heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brain metabolic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Six-Category Diagnosis Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Index Visit Total Diagnostic Utilization Costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Odds of Short-Term Serious Medical Events (SMEs) after Misdiagnosis
Endpoint domain: Adverse events/effects
Primary endpoint: Axillary temperature < 36.5 degrees Celsius
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful insertion of i-gel and LMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Freedom from aneurysm or dissection-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Variation of a marker of endoplasmic reticulum stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline cervical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance to investigational product
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in self-reported global Bowel Symptom Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of scale use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CVLT Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bone union time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: linezolid time over MIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and nature of Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post vaccination concentration IgG ≥5 µg/mL and fold increase Post/Pre ≥2 for at least 6 serotypes out of 11
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence and relationship to vaccination of all serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Shift in Gut Microbiome Diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician Global Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient/Parent Global Activity
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Myositis Disease Activity Assessment Tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient experiences with zygomatic miniplates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: soft tissue profile changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to tobacco use treatment guidelines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Normal Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patients willing to be randomised
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ability to initiate treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ensure patient safety
Endpoint domain: Adverse events/effects
Primary endpoint: Hours Used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prostate Specific Antigen (PSA) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Median duration of interval for resuscitation maneuver initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: DHA incorporation in erythrocyte cellular membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final hearing prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum Rest Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Segments With Resting Perfusion Defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of self-perceived activity of the SLE
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximally Tolerated Dose (MTD) of ME-401 alone
Endpoint domain: Adverse events/effects
Primary endpoint: Dose Limiting Toxicities (DLTs) of ME-401 alone
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluate the safety and tolerability of ME-401 plus rituximab
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of bronchial hypersensitiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Percent Change From Baseline in Serum Lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 1 RM (repetition maximum) strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anaerobic sprint capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in preeclampsia knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Body Mass Index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative Reduction in Donor Skin Area Requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum tolerated dose of ABT-888 with topotecan hydrochloride
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of Sensitization to at Least One Food Allergen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effect of actionable genetic findings on health-care utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pelvic girdle questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: arrival times of acute strokes from stroke symptoms onset to ER
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in stroke knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Successful thoracoscopic ectomies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mombelli Plaque Index (mPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Löe-Silness Gingival Index Score (GI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival Bleeding on Probing (BOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decision to Undergo Cataract Surgery
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Health events of interest
Endpoint domain: Adverse events/effects
Primary endpoint: Complication of disease
Endpoint domain: Adverse events/effects
Primary endpoint: Stone-free result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total post-operative narcotic utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Modified Barthel Index (MBI) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Docking time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fear of hypoglycaemia as measured by the Hypoglycaemia Fear Survey questionnaire (HFS-98)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of Patients Who Are Alive and Progression-free for at Least 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: Frequency and Severity of Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Incremental area under the concentration-time curve (AUC(0-3 h)) of plasma glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ventavis treatment compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time and site of onset and complete release of radiolabel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety - adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of autologous cardiosphere-derived stem cells
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of change in clinical decision making
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of standardized drinks consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DLNO/DLCO ratio changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sustained Virological Response 12 weeks after the end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any major post-biopsy complication event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Neurostatus Expanded Disability Status Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in MS Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Intestinal Fatty Acid Binding Protein (I-FABP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in zonulin-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial changes of plasma lipid fractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiac Autonomic modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Activation of brain areas for autobiographical emotional memory recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Activation of brain areas for reward processing and anhedonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum tolerated dose of AMV564
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preliminary evaluation of AMV564 efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue induction
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Binocular Uncorrected Distance Visual Acuity (UDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: propofol and opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: patient´s and endoscopist´s satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patients' performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Death of the patient
Endpoint domain: Mortality/survival
Primary endpoint: Physical activity measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrathecal viral replication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cellular immune responses against HIV-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Degree of glial activation/proliferation and neuronal dropout
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Polysomnography results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Language problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placebo corrected change in QTcF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of retained users at 10 weeks
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Wound Healing Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary MMP8 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak power per kilogram on single two-legged jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death of any cause and major cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Change in weight bearing pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of renal artery stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Differentiation of focal AIP and Pancreatic malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained objective response (partial response + complete response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the percentage of CD8+ T cells that are PD-1+ due to treatment with pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intestinal cholesterol absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lung inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Physical well-being Q-score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Assessment of proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Decrease in acute migraine pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in myofibrillar fractional synthetic rate (FSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Communication about cardiopulmonary resuscitation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Need for high dose of oxygen or mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline arterial blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follicle-stimulating hormone (FSH) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Anti-Müllerian hormone (AMH) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Antral follicles numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Sensitivity and specificity of EBUS to visualize or exclude PE compared to chest CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of EBUS to identify a clot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of EBUS to identify flow around clot(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy rate measured by detectable embryonic cardiac activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Hb A1C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recovered percentage(%) of the symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the score about the symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage(%) of the patients who have symptom during the daytime
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post Reconstruction Complication Rates
Endpoint domain: Adverse events/effects
Primary endpoint: Antimicrobial Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Inorganic phosphorus (Pi) change from baseline to end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resident's knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Linkage to care and time to ART
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Community viral load before and after the TLC-IDU initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention in Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cotinine-verified 7-day point prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red cell mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Step variability in dual-task walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes